Synthesis, Anticancer Evaluation and Molecular Docking Studies of 1-(2-Fluorobenzyl)piperazine Triazoles: A Novel Breast Cancer Cell Inhibitors

New series of 1-(2-fluorobenzyl)piperazine triazoles 7(a-k) have been synthesized and evaluated for anticancer activity. The molecular structures of all the compounds were established by employing 1H NMR, 13C NMR and mass spectral analysis. In vitro anticancer activity was evaluated using MTT assay against MCF7 breast cancer cell line. Compounds 7i and 7j bearing 4-fluorophenyl and 2-fluorophenyl pendant from triazole substituent phenyl ring exhibited the highest anticancer efficacy with IC50 values of 12.09 µg/mL and 15.12 µg/mL, respectively. A molecular docking study conducted on human HER2 complexed with hercepatin fab was acquired from Protein Data Bank (PDB ID: 1N8Z). Molecular docking studies demonstrated Leu443, Gly442 and Leu27 as key residues interacting with active compounds.